On March, 19 is expected NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY)’s earnings report, as reported by RTT. Analysts have anticipation on stock’s earnings per share of $-0.11. That’s down 650.00 % from last year?s $0.02 earnings per share. Wall Street forecasts 0.00 % EPS growth as of March, 19. NBY reached $1.43 during the last trading session after $0.12 change.NovaBay Pharmaceuticals, Inc. is downtrending after having declined 59.94% since March 10, 2018. NBY has 41,528 volume or 80.39% up from normal. The stock underperformed the S&P500 by 64.31%.

NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops, makes, and markets anti-infective products for the eye care market in the United States.The company has $24.44 million market cap. The Company’s commercial products include the Neutrox family of products, Avenova for the eye care market; Aganocide compounds patented synthetic molecules with a range of spectrum of uses against bacteria, viruses, and fungi; Auriclosene Irrigation Solution for urology; CelleRx for the dermatology market; intelli-Case, a device for soft and rigid gas permeable contact lenses; and NeutroPhase for wound care.Last it reported negative earnings. The firm has collaboration and license agreement with Virbac to develop its Auriclosene compounds for veterinary markets.